Laboratory of Cellular and Molecular Neuroscience (LCMN), School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia.
Int J Mol Sci. 2022 Apr 26;23(9):4788. doi: 10.3390/ijms23094788.
Multiple sclerosis (MS) is a chronic neuroinflammatory and demyelinating disease of the central nervous system (CNS), characterised by the infiltration of peripheral immune cells, multifocal white-matter lesions, and neurodegeneration. In recent years, microglia have emerged as key contributors to MS pathology, acting as scavengers of toxic myelin/cell debris and modulating the inflammatory microenvironment to promote myelin repair. In this review, we explore the role of two neuropeptides, pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP), as important regulators of microglial functioning during demyelination, myelin phagocytosis, and remyelination, emphasising the potential of these neuropeptides as therapeutic targets for the treatment of MS.
多发性硬化症（MS）是一种中枢神经系统（CNS）的慢性神经炎症和脱髓鞘疾病，其特征是外周免疫细胞浸润、多灶性白质病变和神经退行性变。近年来，小胶质细胞已成为 MS 病理学的关键贡献者，它们作为有毒髓磷脂/细胞碎片的清除剂，并调节炎症微环境以促进髓鞘修复。在这篇综述中，我们探讨了两种神经肽，垂体腺苷酸环化酶激活肽（PACAP）和血管活性肠肽（VIP），作为脱髓鞘、髓磷脂吞噬和髓鞘再生过程中小胶质细胞功能的重要调节剂的作用，强调了这些神经肽作为治疗 MS 的治疗靶点的潜力。
